Corbus Pharmaceuticals (CRBP) AI Stock Analysis

• Market Cap: $119.37M
• Dividend Yield: N/A
• Average Volume (3M): 113.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.02
• Revenue Growth: N/A
• EPS Growth: 18.15%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -1.44
• Shares Outstanding: 12,255,225
• 10 Day Avg. Volume: 112,501
• 30 Day Avg. Volume: 113,278
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.25
• Enterprise Value/Revenue: -42.60
• Enterprise Value/Gross Profit: 54.88
• Enterprise Value/Ebitda: 0.52
• 1Y Price Target: $43.50
• Price Target Upside: 334.13% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 43 Neutral
• Price Target: ―

Corbus Pharmaceuticals' overall stock score is driven by severe financial challenges, including no recent revenue and high net losses, which significantly weigh down its score. However, technical indicators suggest some short-term positive momentum. The promising Phase 1 trial results provide a potential catalyst in the biotechnology field, offering some positive outlook despite the current financial difficulties.

Positive Factors

Clinical Data

Corbus disclosed updated data from its ongoing Phase 1 trial, showing a confirmed objective response rate (ORR) of 57% in patients with heavily pretreated head and neck squamous cell carcinoma.

Financial Health

Corbus ended the second quarter with $116.6 million in cash, expected to fund operations through the second quarter of 2027.

Regulatory Approval

FDA granted Fast Track designation for CRB-701 in r/r metastatic cervical cancer, signaling clinical and regulatory alignment.

Negative Factors

Clinical Risk

The duration may be too short to confirm that CRB-913’s greater peripheral restriction fully mitigates neuropsychiatric risk.

Financial Performance

Corbus reported a net loss of $17.7 million, which was worse than the estimate of a loss of $11.0 million.

Short Interest

Short interest in Corbus Pharmaceuticals Holdings is notably high at 17.6% of the float.

Corbus Pharmaceuticals Business Overview & Revenue Model

Company Description

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a clinical-stage pharmaceutical company specializing in the development and commercialization of novel therapeutics for the treatment of inflammatory and fibrotic diseases. The company's primary focus is on harnessing the potential of the endocannabinoid system to develop drugs that address chronic diseases with significant unmet medical needs. Corbus is engaged in developing a pipeline of innovative drug candidates targeting these conditions, with a particular emphasis on rare inflammatory diseases.

How the Company Makes Money

Corbus Pharmaceuticals primarily makes money through the development and commercialization of its drug candidates. The company's revenue model involves advancing its drug pipeline through clinical trials, obtaining regulatory approvals, and subsequently partnering with larger pharmaceutical companies for distribution and commercialization. Key revenue streams include milestone payments from strategic partnerships, licensing agreements, and potential sales of its proprietary drugs once approved. Corbus relies on collaborations with other pharmaceutical companies and research institutions to enhance its research capabilities and expedite the development of its therapeutic candidates, which is crucial for generating future revenue.

Corbus Pharmaceuticals Financial Statement Overview

Summary

Corbus Pharmaceuticals faces severe financial challenges with no revenue in recent periods, high net losses, and cash flow issues. The balance sheet shows some recovery in equity, but financial instability remains a risk. Strategic changes are essential for financial health improvement.

Income Statement

Corbus Pharmaceuticals has faced significant revenue challenges, with zero revenue in recent years and declining gross profit margins. The company's net losses have been substantial, indicating ongoing operational struggles. While total revenue was positive in 2019, it has since dropped to zero, highlighting critical revenue generation issues.

Balance Sheet

The company's financial stability is concerning, with a significant debt load relative to equity, although the debt-to-equity ratio improved in 2024 due to positive equity. The equity ratio shows weak equity backing, but the positive stockholders' equity in 2024 is a recovery sign from previous negative equity.

Cash Flow

Corbus Pharmaceuticals has consistently experienced negative operating and free cash flows, indicating cash burn without adequate inflows from operations. The free cash flow to net income ratio is negative, reflecting inefficient cash usage. However, financing inflows in 2024 improved cash positions, providing temporary relief.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	703.38K	0.00	0.00	0.00	881.71K	3.94M
Gross Profit	-546.00K	-600.00K	-31.17M	-1.49M	-757.53K	3.84M
EBITDA	-57.09M	-37.74M	-44.44M	-38.73M	-54.97M	-121.69M
Net Income	-57.95M	-40.21M	-44.60M	-55.83M	-45.55M	-111.30M
Balance Sheet
Total Assets	125.08M	155.88M	28.27M	66.31M	107.73M	102.29M
Cash, Cash Equivalents and Short-Term Investments	20.04M	149.06M	20.91M	59.20M	97.65M	85.43M
Total Debt	2.46M	3.24M	20.88M	25.09M	26.59M	26.84M
Total Liabilities	14.09M	13.45M	35.18M	33.32M	38.62M	57.02M
Stockholders Equity	110.99M	142.43M	-6.90M	32.99M	69.11M	45.27M
Cash Flow
Free Cash Flow	-57.90M	-41.79M	-36.10M	-37.56M	-48.24M	-100.17M
Operating Cash Flow	-57.90M	-41.79M	-36.10M	-37.54M	-48.18M	-99.69M
Investing Cash Flow	29.23M	-121.31M	35.64M	30.07M	-73.42M	-484.49K
Financing Cash Flow	25.03M	166.58M	-2.82M	-533.62K	60.82M	154.87M

Corbus Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBP, the sentiment is Positive. The current price of 10.02 is above the 20-day moving average (MA) of 9.49, above the 50-day MA of 8.87, and above the 200-day MA of 9.42, indicating a bullish trend. The MACD of 0.29 indicates Positive momentum. The RSI at 58.62 is Neutral, neither overbought nor oversold. The STOCH value of 52.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRBP.

Corbus Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
TCRX	48 Neutral	$99.31M	―	-63.33%	―	-42.94%	―
CRBP	43 Neutral	$119.37M	―	-49.00%	―	―	18.15%
SAVA	43 Neutral	$109.66M	―	-88.95%	―	―	-553.86%
ATOS	36 Underperform	$99.62M	―	-41.66%	―	―	-8.91%
HLVX	35 Underperform	$104.29M	―	-40.31%	―	―	57.64%
BMEA	35 Underperform	$120.80M	―	-170.53%	―	―	22.35%

Corbus Pharmaceuticals Corporate Events

Corbus Pharmaceuticals Announces Board Member Departure

On March 20, 2025, Dr. Peter Salzmann informed Corbus Pharmaceuticals Holdings, Inc. that he will not seek re-election to the Board of Directors at the 2025 annual meeting. Dr. Salzmann will continue his role until the meeting, and his decision was not due to any disagreements with the company. Consequently, the Board will reduce its size from eight to seven members after the meeting.

Corbus Pharmaceuticals Appoints Ian Hodgson as COO

On March 13, 2025, Corbus Pharmaceuticals appointed Ian Hodgson as Chief Operating Officer, effective March 15, 2025. Hodgson, with over 25 years of experience in drug development, previously served as Head of Operations at Corbus and has held various leadership roles in the biotech and pharmaceutical sectors. His appointment is accompanied by a Service Agreement that outlines his compensation and employment terms, including non-compete clauses and provisions for termination under specific circumstances.

Corbus Pharmaceuticals Reports Q4 2024 Financial Results

Corbus Pharmaceuticals reported its Q4 and 2024 financial results, highlighting significant progress in its oncology and obesity programs. The company announced encouraging Phase 1 results for CRB-701 in Western studies, with the FDA granting Fast Track designation for its use in metastatic cervical cancer. The company also plans to start a study for CRB-913 in March 2025. Financially, Corbus reported a net loss of $9.5 million for Q4 2024, with $149 million in cash and investments, expected to fund operations through Q3 2027.

Corbus Pharmaceuticals Reports Promising Phase 1 Trial Results

On February 14, 2025, Corbus Pharmaceuticals announced data from a Phase 1 clinical trial for CRB-701, presented at the ASCO GU Symposium. The trial in the US and UK showed promising safety and efficacy, with no dose-limiting toxicities and encouraging responses in several tumor types, including a first-time exploration in head and neck squamous cell carcinoma. This positions Corbus strongly within the oncology field, potentially impacting stakeholders positively.